Clinical Trials
Threshold Announces Interim Results from Tarloxotinib Program and its Plans to Focus on Evofosfamide and Earlier-Stage Opportunities
Threshold Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company specializing in the development of novel pharmaceutical products and technologies for the treatment of cancer, announced interim data from its two Phase 2 proof-of-concept clinical trials of tarloxotinib Outlined...
Clinical Trials
Novartis announces AMG 334 significantly reduces monthly migraine days in people with episodic migraine
Novartis announced positive topline results from ARISE, the first Phase III study evaluating the efficacy and safety of monthly subcutaneous AMG 334 (erenumab) 70mg in episodic migraine prevention. The study met the primary endpoint, demonstrating a...
Clinical Trials
Advaxis Inc starts New Manufacturing/Laboratory Facility in Princeton
Advaxis, Inc a clinical stage biotechnology company developing cancer immunotherapies, will unveil its new state-of-the-art manufacturing facility in Princeton, N.J., with remarks from Governor Chris Christie, BioNJ President and CEO Debbie Hart and Advaxis CEO Daniel O’Connor. ...
Clinical Trials
Astrazeneca says asthma drug shows positive results in phase III trials
Results from pivotal Phase III trials presented at the ERS International Congress demonstrated that adding benralizumab to standard-of-care medicine significantly reduced exacerbations and improved lung function and asthma symptoms in severe asthma patients with an eosinophilic phenotype, as indicated...
Clinical Trials
CiToxLAB appoints Alan Bartlett as Senior Director, Global Laboratory Operations
CiToxLAB, a leading CRO in the field of non-clinical research, announces that Alan Bartlett has joined the company as Senior Director, Global Laboratory Operations, bringing with him 30 years’ experience in the development and implementation of laboratory support in...
Clinical Trials
Denali Therapeutics Announces First Clinical Trial Application, Key Collaborations And $130M Series B
Denali Therapeutics Inc announced several critical milestones in the company's growth, including its first Clinical Trial Application to initiate a Phase 1 trial, previously undisclosed collaborations and licensing deals, and a $130 million Series B equity financing. ...
Clinical Trials
CSM To Host A Live Webinar On Direct-To-Patient Shipping For Clinical Trials
CSM, a leading provider of clinical trial supply services, will conduct an upcoming webinar, "Discover How Direct-to-Patient Shipping is Changing Clinical Trials." This webinar, hosted by FierceMarkets, will explore how sponsor companies and CROs are adopting...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
















